Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Last month the Oxford Innovation Society (OIS) hosted an event at Pembroke College which celebrated some of the pioneering translational research and innovation coming out of the University’s Medical Sciences Division.

Finger pressing a button marked 'Innovation'

The Oxford Innovation Society event, organised by Oxford University Innovation (OUI) and sponsored by the NIHR Oxford Biomedical Research Centre, included fascinating presentations from a range of Oxford academics and company CEOs.

Sarah Walker, Professor of Medical Statistics and Epidemiology (Nuffield Department of Medicine), urged people to consider antimicrobial resistance as seriously as the climate crisis; and Professor Christopher Buckley, Director of Clinical Research at the Kennedy Institute of Rheumatology, called for a periodic table for medical scientists and physicians.

The story of the SpyBiotech’s protein superglue, an innovation spun out from the Oxford’s Department of Biochemistry, was told by its SEO Mark Leuchtenberger. Other speakers included Dr Cheerag Shirodaria, CEO of Oxford spinout Caristo Diagnostics, who presented the company’s advancements in revolutionising diagnosis and treatment of cardiovascular disease.

Over 100 OIS members, which included researchers and inventors, Oxford spinouts, technology transfer professionals, local companies, and venture capitalists, were given extensive networking opportunities and dinner in Pembroke’s historic dining hall.

Dr Simon Warner, OUI’s Head of Licensing and Ventures for Life Sciences, said: “It’s wonderful to be able to host our second OIS in person again after the pandemic. Our members benefit hugely from face-to-face networking and this evening’s presentations, from the NIHR BRC and leaders in Oxford’s innovation ecosystem, have been informative and thought provoking.”

The next OIS dinner will take place on the 23rd of March. In addition to exclusive events, OIS members can benefit from advanced notification of new technologies available for licence and are provided with a range of opportunities to promote their work or business. Find out more about membership.

More information about Oxford University Innovation and licences and services

Similar stories

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

Multiple Debilitating Pains – New global study shows the experience of Endometriosis is rooted in a person’s genetics

Researchers at the University of Oxford in collaboration with 25 teams across the world have published the largest study to date of the genetic basis of endometriosis.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.

Showcasing Oxford’s translational research for Rare Disease Day

Rare Disease Day is an annual awareness day that aims to educate and raise awareness for the 400 million people worldwide who live with a rare disease.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.